胃と腸54巻7号

2019年06月発行

今月の主題 A型胃炎—最新の知見 主題

A型胃炎を背景とした胃神経内分泌腫瘍（胃NET）の特徴

著者： 佐藤祐一¹ 横山邦彦¹ 渡邉順¹ 中村厚夫¹ 橋本哲² 寺井崇二²

所属機関： ¹新潟県立吉田病院消化器内科 ²新潟大学大学院医歯学総合研究科消化器内科学

ページ範囲：P.1019 - P.1023

要旨●A型胃炎を背景に発生する胃NETは，I型胃NETに分類され，腫瘍径は小さく多発性であり，病理組織学的にも低悪性度で，予後がよいのが特徴とされる．本邦をはじめとしたこれまでの報告は，そのような特徴に沿うものが多かった．しかし，最近になり，リンパ節転移や肝転移を来すI型胃NET症例が，低頻度ながら存在することが明らかになり，その臨床的特徴として，①腫瘍径10mm以上，②Ki-67 index高値，③固有筋層以深の深部浸潤，などの危険因子が挙げられている．現在，本邦のI型胃NETの研究において，200例の登録が終了し，データの解析に入っており，その結果が注目される．

参考文献

1）Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman FT, Carneiro F, Hruban RH, et al（eds）. WHO Classification of Tumours of the Digestive System. IARC, Lyon, pp 13-14, 2010

2）佐藤祐一，今村祐志，海崎泰治，他．胃カルチノイドの長期経過．胃と腸　52：431-440, 2017

3）Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol　45：234-243, 2010

4）Sato Y, Iwafuchi M, Ueki J, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan：a relationship with Helicobacter pylori infection. Dig Dis Sci　47：579-585, 2002

5）Solcia E, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the stomach. In Bosman FT, Carneiro F, Hruban RH, et al（eds）. WHO Classification of Tumours of the Digestive System. IARC, Lyon, pp 64-68, 2010

6）Sato Y, Hashimoto S, Mizuno K, et al. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol　22：6817-6828, 2016

7）Attili F, Capurso G, Vanella G, et al. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis　46：9-17, 2014

8）日本神経内分泌腫瘍研究会（JNETS）（編）．膵・消化管神経内分泌腫瘍（NET）診療ガイドライン，第1版．金原出版，p 9, 2015

9）Sato Y, Takeuchi M, Hashimoto S, et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology　60：1524-1529, 2013

10）Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients：retrospective, multicenter study in Japan. Dig Endosc　26：377-384, 2014

11）Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids：biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg　242：64-73, 2005

12）Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors：data from a multicenter study. Eur J Endocrinol　168：185-193, 2013

13）Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids：a prospective study on endoscopic management and recurrence rate. Neuroendocrinology　95：207-213, 2012

14）Campana D, Ravizza D, Ferolla P, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis：a retrospective, multicentre study. Endocrine　51：131-139, 2016

15）Chen WC, Warner RR, Ward SC, et al. Management and disease outcome of type I gastric neuroendocrine tumors：the Mount Sinai experience. Dig Dis Sci　60：996-1003, 2015

16）La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol　42：1373-1384, 2011

17）Manfredi S, Walter T, Baudin E, et al. Management of gastric neuro-endocrine tumours in a large French national cohort（GTE）. Endocrine　57：504-511, 2017

18）Vanoli A, La Rosa S, Miceli E, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms：Analysis of 200 cases with extended follow-up. Neuroendocrinology　107：114-126, 2018

19）Spampatti MP, Massironi S, Rossi RE, et al. Unusually aggressive type 1 gastric carcinoid：a case report with a review of the literature. Eur J Gastroenterol Hepatol　24：589-593, 2012

20）Chung CS, Tsai CL, Chu YY, et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment：A Digestive Endoscopy Society of Tawian（DEST）. Medicine（Baltimore）　97：e12101, 2018

21）Sagatun L, Fossmark R, Jianu CS, et al. Follow-up of patients with ECL cell-derived tumours. Scand J Gastroenterol　51：1398-1405, 2016

22）Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid：a real threat or just a myth? World J Gastroenterol　19：8687-8695, 2013

23）Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol　18：2826-2832, 2011